Dare Bioscience Inc (NASDAQ:DARE) was the target of a significant decrease in short interest in the month of August. As of August 31st, there was short interest totalling 161,900 shares, a decrease of 20.8% from the August 15th total of 204,500 shares. Based on an average daily trading volume, of 929,000 shares, the short-interest ratio is presently 0.2 days.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Founders Financial Securities LLC lifted its holdings in Dare Bioscience by 387.5% in the 2nd quarter. Founders Financial Securities LLC now owns 97,500 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 77,500 shares in the last quarter. HighTower Advisors LLC raised its stake in shares of Dare Bioscience by 62.4% in the second quarter. HighTower Advisors LLC now owns 26,034 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 10,000 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Dare Bioscience in the second quarter worth about $41,000. Finally, UBS Group AG purchased a new position in shares of Dare Bioscience in the first quarter worth about $32,000. 5.15% of the stock is currently owned by institutional investors.

Several equities analysts recently weighed in on the stock. Aegis restated a “market perform” rating and issued a $5.00 price objective on shares of Dare Bioscience in a report on Sunday, July 12th. Maxim Group reissued a “buy” rating and set a $3.00 price objective on shares of Dare Bioscience in a research report on Thursday, June 18th. Dawson James reissued a “buy” rating and set a $3.00 price objective on shares of Dare Bioscience in a research report on Sunday, July 12th. Roth Capital reissued a “buy” rating on shares of Dare Bioscience in a research report on Thursday, September 10th. Finally, ValuEngine downgraded shares of Dare Bioscience from a “buy” rating to a “hold” rating in a research report on Tuesday, July 14th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Dare Bioscience has a consensus rating of “Buy” and a consensus price target of $4.50.

DARE traded down $0.01 during trading on Friday, hitting $1.05. 1,200 shares of the company traded hands, compared to its average volume of 1,048,356. The firm has a market cap of $33.45 million, a P/E ratio of -1.23 and a beta of 1.90. The stock’s fifty day moving average is $1.11 and its 200 day moving average is $1.05. Dare Bioscience has a one year low of $0.69 and a one year high of $2.22.

Dare Bioscience (NASDAQ:DARE) last posted its quarterly earnings results on Wednesday, August 12th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.13). On average, research analysts anticipate that Dare Bioscience will post -0.67 earnings per share for the current fiscal year.

Dare Bioscience Company Profile

Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.

See Also: Dow Jones Industrial Average (DJIA)

Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.